BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 9, 2025
See today's BioWorld
Home
» Celyad shares drop 40% on cell therapy phase III miss in heart failure
To read the full story,
subscribe
or
sign in
.
Celyad shares drop 40% on cell therapy phase III miss in heart failure
June 29, 2016
By
Cormac Sheridan
No Comments
DUBLIN – Shares in Celyad SA fell 40 percent in Brussels Tuesday on news that its C-Cure stem cell therapy failed to reach the primary endpoint of a phase III trial in patients with congestive heart failure.
BioWorld